RIPK3 and Sepsis: Recently, the MESSI (Molecular Epidemiology of SepsiS in the Intensive care unit) trial, which is a prospective study with 120 patients, suggested a correlation between increased plasma levels of the necrosome-related RIPK3 and the development of ARDS during sepsis (55).